The Effect of COVID-19 Vaccine Acceptance, Intention, and/or Hesitancy and Its Association with Our Health and/or Important Areas of Functioning.

In the quest to understand and improve the COVID-19 vaccination drive, some researchers assume that some COVID-19-related variables - such as COVID-19 stress, fear of COVID-19, perceived stigma from COVID-19, self-stigma from COVID-19, and believing COVID-19 information - may be helpful in this regard [[16], [18]]. As of 12 January 2022, nine vaccines have obtained WHO Emergency Use Listing, including the Pfizer/BioNTech Comirnaty vaccine (31 December 2020); SII/COVISHIELD and AstraZeneca/AZD1222 vaccines (16 February 2021); Janssen/Ad26.COV 2.S vaccine (by Johnson & Johnson, New Jersey, US, 12 March 2021); Moderna COVID-19 vaccine (mRNA 1273, 30 April 2021); Sinopharm COVID-19 vaccine (7 May 2021); Sinovac-CoronaVac vaccine (1 June 2021); Bharat Biotech BBV152 COVAXIN vaccine (3 November 2021); Covovax (NVX-CoV2373) vaccine (17 December 2021); and Nuvaxovid (NVX-CoV2373) vaccine (20 December 2021) [[14]]. A comparative study on physical and mental health outcomes between vaccinated and unvaccinated COVID-19 participants with respect to post-COVID-19 infection may squash vaccination hesitancy and push forward COVID-19 vaccination. However, a previous study examining the difference between COVID-19 and flu vaccination programmes revealed that flu vaccination rates have been affected after COVID-19 vaccination [[36]]. [Extracted from the article]